Amphastar Pharmaceuticals Inc. (AMPH)
Amphastar Pharmaceuticals Inc. (AMPH) Q1 2025 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants David Amsellem - Piper Sandler Cerena Chen - Wells Fargo Jason Gerberry - Bank of America Ekaterina Knyazkova - JPMorgan Operator Greetings and welcome to the Amphastar Pharmaceuticals First Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $1.04 per share a year ago.
Is the Options Market Predicting a Spike in Amphastar (AMPH) Stock?
Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.
Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds
On Thursday, Amphastar Pharmaceuticals Inc. AMPH reported fourth-quarter adjusted EPS of 92 cents, up from 88 cents a year ago, but missing the consensus of 94 cents.
Amphastar: Earnings Miss, Margins Drop
Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.
Amphastar Pharmaceuticals Inc. (AMPH) Q4 2024 Earnings Call Transcript
Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberry - Bank of America Cerena Chen - Wells Fargo Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Serge Belanger - Needham & Company Operator Greetings and welcome to the Amphastar Pharmaceuticals Fourth Quarter Earnings Call. At this time, all participants are in a listen-only mode.
Amphastar (AMPH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.92 per share, missing the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.88 per share a year ago.
Amphastar Pharmaceuticals: A Gradual Strategy
Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside.
Amphastar Pharmaceuticals: Cheap With Caveats
Amphastar Pharmaceuticals' stock has declined over 25% since early November, despite solid earnings and sales growth, presenting a potential buying opportunity. Q3 results were impacted somewhat by the effects of Hurricane Helene, after easily exceeding top and bottom-line expectations in Q2. The stock is cheap on a P/E basis, but there are some caveats, including patent expiration in early 2026 on a key product.
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at Click Here
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at Click Here
